Provided by Tiger Trade Technology Pte. Ltd.

Editas Medicine

3.06
-0.1000-3.16%
Post-market: 3.060.00000.00%17:24 EDT
Volume:2.08M
Turnover:6.40M
Market Cap:468.18M
PE:-4.19
High:3.14
Open:3.12
Low:3.03
Close:3.16
52wk High:4.54
52wk Low:1.66
Shares:153.00M
Float Shares:115.00M
Volume Ratio:0.68
T/O Rate:1.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7307
EPS(LYR):-1.8036
ROE:-118.82%
ROA:-23.29%
PB:4.45
PE(LYR):-1.70

Loading ...

Editas Medicine patent interference narrows; USPTO reaffirms PTAB ruling favoring Broad Institute

Reuters
·
Mar 27

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), DocGo (DCGO) and Editas Medicine (EDIT)

TIPRANKS
·
Mar 17

Regulatory Disruptions at FDA Threaten Editas Medicine’s Gene-Editing Timelines and Commercial Prospects

TIPRANKS
·
Mar 11

Editas Medicine upgraded to Buy from Hold at JonesResearch

TIPRANKS
·
Mar 10

Wells Fargo Sticks to Its Hold Rating for Editas Medicine (EDIT)

TIPRANKS
·
Mar 10

Clear Street Reaffirms Their Buy Rating on Editas Medicine (EDIT)

TIPRANKS
·
Mar 10

Editas Medicine Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 10

Editas Medicine Shares Jump on Narrower 4Q Loss, Revenue Beat

Dow Jones
·
Mar 09

Editas Medicine Q4 EPS $(0.06) Beats $(0.25) Estimate, Sales $24.741M Beat $5.595M Estimate

Benzinga Earnings
·
Mar 09

Editas Medicine posts smaller‑than‑expected Q4 net loss on lower R&D spend

Reuters
·
Mar 09

BRIEF-Editas Medicine Q4 Net Income USD -5.62 Million Vs. IBES Estimate USD -24.3 Million

Reuters
·
Mar 09

Editas Medicine Q4 Operating Expenses USD 32.496 Million

THOMSON REUTERS
·
Mar 09

Editas Medicine Q4 Operating Income USD -7.755 Million

THOMSON REUTERS
·
Mar 09

Editas Medicine Q4 EPS USD -0.06

THOMSON REUTERS
·
Mar 09

Editas Medicine Q4 Collaboration and Other Research and Development Revenue USD 24.7 Million

THOMSON REUTERS
·
Mar 09

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

GlobeNewswire
·
Mar 09